Neurodegenerative diseases, like Alzheimer’s and Parkinson’s disease are caused by progressive damage to cells of the nervous system. Patients suffering from these debilitating disorders lose their mobility, balance, speech, and so many other important functions. Scientists studying these disorders need advanced cell models that have the physiological and pharmacological properties seen in mature neurons. [Read more…]
Human Induced Pluripotent Stem Cell (iPSC) Derived Tissues – Present & Future Outlook
In this article, the present and future outlook for human iPSC-derived tissues is explored. Induced pluripotent stem cells (iPSCs) are differentiated cells that are reprogrammed into a pluripotent state, allowing a wide range of cell and tissue types to be derived from them.
Key findings include:
- iPSC technology is moving from a boutique phenomenon to industrialized cellular models.
- Increasing recognition by industry and regulatory bodies for detecting a variety of toxicities.
- Emerging utility for predicting cardio and neuro-related oncology adverse effects.
Leading Competitors within the Induced Pluripotent Stem Cell (iPSC) Market
Since the discovery of induced pluripotent stem cells (iPSCs) in 2006, a large and thriving research products market has emerged, largely because the cells are non-controversial and can be generated directly from adult cells. It is clear that iPSCs represent a lucrative market segment, because methods for commercializing this cell type are expanding every year and clinical studies investigating iPSCs are swelling in number. [Read more…]
iPSCs are Transforming Drug Discovery, Toxicity Testing, Disease Modeling, and Beyond
Induced pluripotent stem cells (iPS cells or iPSCs) are laboratory-made pluripotent stem cells that are produced using adult cells. They are derived from somatic cells by reprogramming artificially and turning on the expression of specific pluripotency genes. The reprogramming is achieved using different techniques with varying efficiencies. The iPSC technology was first discovered in 2006 by Shinya Yamanaka’s lab in Kyoto, Japan. He and his team introduced four specific genes encoding transcription factors and converted adult cells into pluripotent stem cells. [Read more…]
Chinese Patent Granted for CytoMed Therapeutics’ Licensed iPSC-Based Technology
SINGAPORE — CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced that its exclusively licensed induced pluripotent stem cell (iPSC)-based technology has been granted a patent by the China National Intellectual Property Administration (CNIPA). [Read more…]
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 68
- Next Page »